Material Event - Form 8-K

On March 28, 2024, Vaccinex, Inc. (the "Company") closed a registered direct offering of an aggregate of 193,000 shares (the "Shares") of the Company's common stock (the "Common Stock") and a concurrent private placement of warrants ("Common Warrants") to purchase up to 193,000 shares of Common Stock at a combined price of $7.77 per Share and Common Warrant (the "Offering"), for aggregate gross proceeds of approximately $1.5 million. The Offering was previously disclosed in a Current Report on Form 8-K and press release on March 27, 2024. A copy of the legal opinion of Hogan Lovells US LLP relating to the legality of the issuance and sale of the Shares in the Offering is filed herewith as Exhibit 5.1.